Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 1.00 |
| ▸ | INSR | P06213 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.76 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.76 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.76 |
| ▸ | GSK3A | P49840 | 2/20 | 0.65 |
| ▸ | GSK3B | P49841 | 2/20 | 0.65 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.65 |
| ▸ | MYC | P01106 | 1/20 | 0.64 |
| ▸ | IL1RN | P18510 | 1/20 | 0.64 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.64 |
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.59 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363656 | 1.00 | IGF1R (1.00) | IGF1RINSRCDK2PIK3CGHSPD1 | |
| SCHEMBL12989670 | 1.00 | IGF1R (1.00) | IGF1RINSRCDK2PIK3CGHSPD1 | |
| SCHEMBL13388565 | 0.89 | INSR (0.80) | IGF1RINSRCDK2PIK3CGHSPD1 | |
| SCHEMBL1064248 | 0.89 | IGF1R (0.80) | IGF1RINSRCDK2PIK3CGHSPD1 | |
| SCHEMBL1064250 | 0.89 | IGF1R (0.80) | IGF1RINSRCDK2PIK3CGHSPD1 | |
| SCHEMBL3363802 | 0.89 | IGF1R (0.80) | IGF1RINSRCDK2PIK3CGHSPD1 | |
| SCHEMBL21067321 | 0.87 | CDK2 (1.00) | IGF1RINSRCDK2PIK3CGHSPD1 | |
| SCHEMBL12989666 | 0.86 | PIK3CG (1.00) | IGF1RINSRCDK2PIK3CGHSPD1 | |
| SCHEMBL3364886 | 0.86 | PIK3CG (1.00) | IGF1RINSRCDK2PIK3CGHSPD1 | |
| SCHEMBL3364888 | 0.86 | PIK3CG (1.00) | IGF1RINSRCDK2PIK3CGHSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759536-B2 | Rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients | AVIXGEN INC. (KR) | 2014-06-24 | — | — | US | claimed |
| EP-2583969-A2 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | claimed |
| US-20130096125-A1 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PAHRMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | claimed |
| US-8759536-B2 | Rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients | AVIXGEN INC. (KR) | 2014-06-24 | — | — | US | disclosed |
| US-8735445-B2 | Inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of the skin or skin appendages | L'OREAL (FR) | 2014-05-27 | — | — | US | disclosed |
| US-8735445-B2 | Inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of the skin or skin appendages | L'OREAL (FR) | 2014-05-27 | — | — | US | disclosed |
| EP-2583969-A2 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096125-A1 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PAHRMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
| US-20110014250-A1 | INHIBITORS OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE FOR STIMULATING PIGMENTATION OF THE SKIN OR SKIN APPENDAGES | L'OREAL (FR) | 2011-01-20 | — | — | US | disclosed |
| US-20110014250-A1 | INHIBITORS OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE FOR STIMULATING PIGMENTATION OF THE SKIN OR SKIN APPENDAGES | L'OREAL (FR) | 2011-01-20 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20080076809-A1 | Heterocyclic compound for stimulating or inducing the growth of the hair or eyelashes and/or slowing down their loss composition comprising it and its uses | SOCIETE L'OREAL S.A. (FR) | 2008-03-27 | — | — | US | disclosed |
| US-20080076809-A1 | Heterocyclic compound for stimulating or inducing the growth of the hair or eyelashes and/or slowing down their loss composition comprising it and its uses | SOCIETE L'OREAL S.A. (FR) | 2008-03-27 | — | — | US | disclosed |
| US-7294641-B2 | Heterocyclic compound for stimulating or inducing the growth of the hair or eyelashes and/or slowing down their loss, composition comprising it and its uses | L'OREAL (FR) | 2007-11-13 | — | — | US | disclosed |
| US-7294641-B2 | Heterocyclic compound for stimulating or inducing the growth of the hair or eyelashes and/or slowing down their loss, composition comprising it and its uses | L'OREAL (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | TRIAD THERAPEUTICS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-20040009526-A1 | Common ligand mimics: thiazolidinediones and rhodanines | YU LIN (US) | 2004-01-15 | — | — | US | disclosed |
| WO-2003081209-A2 | IDENTIFICATION OF LIGANDS FOR A RECEPTOR FAMILY AND RELATED METHODS | TRIAD THERAPEUTICS, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20030180797-A1 | Identification of ligands for a receptor family and related methods | TRIAD THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003072033-A2 | COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES | TRIAD THERAPEUTICS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076809-A1 | Heterocyclic compound for stimulating or inducing the growth of the hair or eyelashes and/or slowing down their loss composition comprising it and its uses | KRT18, FGF1, SHH | IGF1R 244/4885INSR 2739/4885CDK2 327/4885 |
| US-20040009526-A1 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | IGF1R 48/4885INSR 20/4885CDK2 2106/4885 |
| US-20130096125-A1 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PAHRMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | LRAT, MRM1, ADH7 | IGF1R 4354/4885INSR 4383/4885CDK2 966/4885 |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | IGF1R 522/4885INSR 1642/4885CDK2 3/4885 |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | IGF1R 48/4885INSR 20/4885CDK2 2106/4885 |
| US-20110014250-A1 | INHIBITORS OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE FOR STIMULATING PIGMENTATION OF THE SKIN OR SKIN APPENDAGES | COX15, HPGD, TYR | IGF1R 4087/4885INSR 4579/4885CDK2 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.